Immunitybio Financials
| IBRX Stock | USD 5.04 0.06 1.18% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.79 | 5.0458 |
|
|
The financial analysis of Immunitybio is a critical element in measuring its lifeblood. Investors should not minimize Immunitybio's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Immunitybio | Select Account or Indicator |
Understanding current and past Immunitybio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immunitybio's financial statements are interrelated, with each one affecting the others. For example, an increase in Immunitybio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Immunitybio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunitybio. Check Immunitybio's Beneish M Score to see the likelihood of Immunitybio's management manipulating its earnings.
Immunitybio Stock Summary
Immunitybio competes with BioLineRx, Ardelyx, Lexicon Pharmaceuticals, Seres Therapeutics, and Protalix Biotherapeutics. ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US45256X1037 |
| CUSIP | 45256X103 63016Q102 |
| Location | California; U.S.A |
| Business Address | 3530 John Hopkins |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | immunitybio.com |
| Phone | 844 696 5235 |
| Currency | USD - US Dollar |
Immunitybio Key Financial Ratios
| Operating Margin | (13.14) % | ||||
| Price To Sales | 479.00 X | ||||
| Revenue | 622 K | ||||
| Gross Profit | 240 K | ||||
| EBITDA | (436.18 M) |
Immunitybio Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 143.1M | 221.4M | 468.9M | 362.4M | 504.5M | 288.0M | |
| Other Current Liab | 5.8M | 51.6M | 52.3M | 45.3M | 43.8M | 25.3M | |
| Net Debt | (660K) | 240.6M | 464.6M | 619.1M | 461.3M | 484.3M | |
| Retained Earnings | (662.2M) | (1.6B) | (2.0B) | (2.4B) | (3.0B) | (2.8B) | |
| Accounts Payable | 1.7M | 11.5M | 11.4M | 21.0M | 9.2M | 7.2M | |
| Cash | 15.5M | 34.9M | 181.1M | 104.6M | 265.5M | 278.7M | |
| Net Receivables | 303K | 2.0M | 1.3M | 1.9M | 3.2M | 2.7M | |
| Other Current Assets | 3.8M | 9.2M | 15.9M | 31.5M | 24.5M | 25.7M | |
| Total Liab | 22.4M | 339.9M | 712.8M | 812.2M | 1.1B | 1.1B | |
| Total Current Assets | 55.8M | 111.7M | 334.3M | 140.6M | 294.1M | 172.1M | |
| Intangible Assets | 12.1M | 1.5M | 1.4M | 20.0M | 17.1M | 17.9M | |
| Common Stock | 10K | 38K | 40K | 42K | 67K | 70.4K | |
| Other Assets | 1.0 | 7.6M | 6.4M | 6.6M | 7.6M | 4.4M | |
| Capital Surpluse | 783.0M | 1.5B | 1.7B | 1.9B | 2.2B | 1.3B | |
| Other Liab | 8.3M | 1.6M | 411K | 22.0M | 25.3M | 26.6M | |
| Net Tangible Assets | (118.6M) | (236.5M) | (243.6M) | (467.3M) | (420.6M) | (399.6M) |
Immunitybio Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 5.9M | 9.1M | 14.8M | 63.5M | 129.2M | 135.7M | |
| Total Revenue | 2.2M | 605K | 934K | 240K | 622K | 617.8K | |
| Gross Profit | (6.8M) | (8.5M) | 934K | (24.0M) | (17.9M) | (17.0M) | |
| Operating Income | (156.3M) | (220.9M) | (330.3M) | (351.3M) | (362.3M) | (344.1M) | |
| Ebit | (156.3M) | (197.1M) | (334.5M) | (359.7M) | (454.7M) | (432.0M) | |
| Research Development | 112.0M | 139.5M | 196.0M | 248.1M | 232.4M | 117.5M | |
| Ebitda | (140.0M) | (187.9M) | (315.4M) | (335.5M) | (436.2M) | (414.4M) | |
| Income Before Tax | (160.3M) | (226.0M) | (349.8M) | (417.3M) | (583.9M) | (554.7M) | |
| Net Income | (160.2M) | (224.2M) | (349.8M) | (417.3M) | (583.2M) | (554.0M) | |
| Income Tax Expense | (105K) | (1.8M) | 9K | 34K | (40K) | (42K) | |
| Tax Provision | (97K) | 5K | 9K | 34K | 39.1K | 41.1K | |
| Interest Income | 1.6M | 1.2M | 836K | 2.7M | 2.0M | 1.9M | |
| Minority Interest | 3.7M | 1.3M | (3.1M) | (753K) | 745K | 782.3K |
Immunitybio Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Immunitybio. It measures of how well Immunitybio is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Immunitybio brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Immunitybio had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Immunitybio has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (19.3M) | (40.9M) | 146.2M | (76.3M) | 160.8M | 168.9M | |
| Free Cash Flow | (156.4M) | (173.4M) | (308.0M) | (436.9M) | (397.3M) | (377.5M) | |
| Depreciation | 14.0M | 12.7M | 14.2M | 18.3M | 18.5M | 9.8M | |
| Other Non Cash Items | 6.2M | 24.1M | 23.1M | 29.4M | 144.8M | 152.0M | |
| Capital Expenditures | 4.3M | 1.7M | 33.6M | 99.4M | 30.6M | 22.7M | |
| Net Income | (160.2M) | (224.2M) | (349.8M) | (417.3M) | (583.2M) | (554.0M) | |
| End Period Cash Flow | 76.0M | 35.1M | 181.3M | 105.0M | 265.5M | 278.7M | |
| Investments | (499K) | (193K) | (71.8M) | 126.7M | (51.6M) | (49.0M) | |
| Net Borrowings | 47.7M | 63.7M | 338.5M | 174.1M | 200.2M | 145.1M | |
| Change To Netincome | (672K) | 12.7M | 58.3M | 29.0M | 33.4M | 25.1M |
Immunitybio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunitybio's current stock value. Our valuation model uses many indicators to compare Immunitybio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunitybio competition to find correlations between indicators driving Immunitybio's intrinsic value. More Info.Immunitybio is rated below average in return on asset category among its peers. It is rated below average in operating margin category among its peers . At this time, Immunitybio's Operating Profit Margin is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunitybio's earnings, one of the primary drivers of an investment's value.Immunitybio Systematic Risk
Immunitybio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immunitybio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Immunitybio correlated with the market. If Beta is less than 0 Immunitybio generally moves in the opposite direction as compared to the market. If Immunitybio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immunitybio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immunitybio is generally in the same direction as the market. If Beta > 1 Immunitybio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Immunitybio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunitybio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Immunitybio growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Immunitybio November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Immunitybio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immunitybio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunitybio based on widely used predictive technical indicators. In general, we focus on analyzing Immunitybio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunitybio's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.78 | |||
| Information Ratio | 0.05 | |||
| Maximum Drawdown | 35.54 | |||
| Value At Risk | (7.80) | |||
| Potential Upside | 13.0 |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.